UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ IQVIA HOLDINGS INC. (Exact name of registrant as specified in its charter) _________________________________________________________ (State or other jurisdiction of incorporation or organization) Delaware 27-1341991 (I.R.S. Employer Identification Number) FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 ______ ...

IQVIA Holdings Inc. (NYSE:IQV) Q1 2023 Earnings Conference Call April 27, 2023 9:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Perrone - Senior Director, Investor Relations Conference Call Participants ...

Market Value and Stock Information - The company's aggregate market value of voting and non-voting common stock held by non-affiliates was approximately $40.2 billion as of June 30, 2022[7] - The company has approximately 185,722,621 shares of common stock outstanding as of February 6, 2023[7] Data and Information Assets - The company's proprietary data set contains approximately 60 petabytes of data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally[26] - The company's data includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records[26] - The company delivers information and insights on over 85% of the world's pharmaceuticals, as measured by 2021 sales[26] - The company receives approximately 100 billion healthcare records annually[27] - The company's proprietary data set includes product level tracking in 93 markets[27] - The company's data set covers treatments and outcomes on more than 1.2 billion unique non-identified patient records globally[27] - The company has one of the largest and most comprehensive collections of healthcare information, including over 1.2 billion non-identified patient records and approximately 60 petabytes of proprietary data[26] - The company's healthcare-specific global IT infrastructure processes approximately 100 billion healthcare records annually, applying privacy, security, and operational protections[27] - The company's analytics-driven clinical development leverages product-level tracking in 93 markets and information on treatments and outcomes from over 1.2 billion unique non-identified patient records[27] - The company's information networks include more than 1.2 billion unique non-identified patient records globally[39] - The company’s information networks include more than 1.2 billion unique non-identified patient records globally[39] Market Opportunity and Industry Trends - The company's market opportunity is estimated to be greater than $300 billion, consisting of outsourced research and development, real-world evidence, and connected health and technology-enabled clinical and commercial operations markets[28] - The life sciences industry generated approximately $1.48 trillion in revenues in 2022, with expected global revenue growth ranging from 3% to 6% between 2023 and 2027[29] - Pharmaceutical spending in emerging markets is projected to grow at a 5% to 8% CAGR through 2027[29] - Biopharmaceutical spending on drug development totaled approximately $160 billion in 2022, with an outsourced portion estimated at $43 billion[29] - The total addressable market for Real-World Evidence and connected health is approximately $62 billion, with $22 billion in life sciences and $40 billion in connected healthcare[29] - The total addressable market for technology-enabled commercial operations is approximately $78 billion, including IT services and commercial services[29] - Approximately 300 new molecular entities (NMEs) are expected to be approved between 2023 and 2027, averaging 60 per year[30] - The company estimates the total market for research and development and commercial operations to be more than $300 billion in 2022[40] - The company's market opportunity is estimated to be greater than $300 billion, encompassing outsourced research and development, real-world evidence, and technology-enabled clinical and commercial operations markets[28] - The company's market size estimates are derived from third-party sources, internal research, and projected growth rates for various segments[28] - The life sciences industry generated approximately $1.48 trillion in revenues in 2022, with expected global revenue growth ranging from 3% to 6% between 2023 and 2027[29] - Spending on pharmaceuticals in emerging markets is projected to grow at a 5% to 8% CAGR through 2027[29] - Biopharmaceutical spending on drug development totaled approximately $160 billion in 2022, with an outsourced portion estimated at $43 billion[29] - The total addressable market for Real-World Evidence and connected health is approximately $62 billion, split into $22 billion for life sciences and $40 billion for connected healthcare[29] - The technology-enabled commercial operations market is valued at approximately $78 billion, including IT services and commercial services[29] - Approximately 300 new molecular entities (NMEs) are expected to be approved between 2023 and 2027, averaging 60 per year[30] - The company’s client base includes over 10,000 clients in over 100 countries, with a total estimated market for research and development and commercial operations exceeding $300 billion in 2022[40] Workforce and Organizational Structure - The company has a global workforce of approximately 86,000 employees, including 29,000 in Technology & Analytics Solutions and 46,000 in Research & Development Solutions[29] - The company has a global workforce of approximately 86,000 employees, including 29,000 in Technology & Analytics Solutions and 46,000 in Research & Development Solutions[29] Client and Revenue Information - No single client accounted for 10% or more of the company's total revenues in 2022, with the largest client contributing approximately 7%[56] - No single client accounted for 10% or more of the company’s total revenues in 2022, with the largest client contributing approximately 7%[56] Competitive Landscape - The company operates in a highly competitive market for Research & Development Solutions, competing against traditional CROs, biopharmaceutical companies, universities, and teaching hospitals[58] - The company's primary competitors include Labcorp Drug Development, ICON plc, Parexel International Corporation, Pharmaceutical Product Development, Inc. (now part of Thermo Fisher Scientific Inc.), and Syneos Health[58] - The company operates in a highly competitive market for Research & Development Solutions, competing against traditional CROs, biopharmaceutical companies, universities, and teaching hospitals[58] Product and Service Offerings - The company offers hundreds of distinct services, applications, technology platforms, and solutions across three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions[43] - The company's real-world solutions ecosystem includes retrospective database analytics, prospective real-world data collection technology platforms, and scientific expertise[27] - The company's proprietary clinical and commercial applications support clients in increasing clinical operations performance, regulatory compliance, and sales operations management[27] - The company offers hundreds of distinct services, applications, technology platforms, and solutions across three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions[43] - The company's offerings complement each other and can provide enhanced value to clients when delivered together, with each segment driving demand for the other[43]

IQVIA Holdings (NYSE:IQV) Q4 2022 Earnings Conference Call February 10, 2023 9:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Perrone - Senior Director, Investor Relations Conference Call Participants D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ (State or other jurisdiction of incorporation or organization) Delaware 27-1341991 (I.R.S. Employer Identification Number) FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION ...

IQVIA Holdings (NYSE:IQV) Q3 2022 Earnings Conference Call October 26, 2022 9:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Conference Call Participants Dave Windley - Jefferies John Sourbeer - UBS Sandy Draper - Guggenheim Shlomo Rosenbaum - Stifel Justin Bowers - Deutsche Bank Patrick Donnelly - Citi Luke Sergott - Barclays Operator L ...

| --- | --- | |-----------------------|-------| | | | | | | | | | | Q3 2022 Earnings Call | | | October 26, 2022 | | IQVIA Template (V2.1.0) Legal IQVIA Template (V2.1.0) 1 This presentation should be viewed in conjunction with IQVIA's Q3 2022 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 _______ ...

IQVIA Holdings Inc. (NYSE:IQV) Q2 2022 Earnings Conference Call July 21, 2022 9:00 AM ET Company Participants Ari Bousbib - Chairman, Chief Executive Officer Ron Bruehlman - Executive Vice President, Chief Financial Officer Mike Fedock - Senior Vice President, Financial Planning and Analysis Nick Childs - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Sandy Draper - Guggenheim Eric Coldwell - Baird Elizabeth Anderson - Evercore Derik de Bruin - Bank of A ...